Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

IOL Position and Refractive Change After Nd:YAG Laser Posterior Capsulotomy (YAG-IOL-POS)

30 de agosto de 2026 atualizado por: Pia Veronika Vécsei-Marlovits, MD, Vienna Hospital Association

Intraocular Lens Position Stability, Anterior Segment Parameters, and Refractive Change Following Nd:YAG Laser Posterior Capsulotomy: A Prospective Multi-Device Assessment Using Swept-Source OCT Biometry (IOLMaster 700), Anterior Segment OCT (CASIA2), and Scheimpflug Tomography (Pentacam AXL)

After cataract surgery, the thin natural membrane that holds the artificial lens in place can slowly turn cloudy. This is called posterior capsule opacification. It makes vision blurry and can cause glare. The standard treatment is a short, painless laser procedure called Nd:YAG capsulotomy, which opens a small clear window in the cloudy membrane.

Opening this membrane changes the support structure around the artificial lens. Eye doctors do not agree on what happens next. Some studies found that the lens shifts slightly backward in the eye after the laser treatment, some found that it shifts forward, and some found no movement at all. It is also unclear whether such a small shift changes how well a person sees or the strength of their glasses. One reason for these mixed results may be that each study used a different imaging device, and these devices measure the depth of the front chamber of the eye in different ways.

This study measures the position of the artificial lens in the same eye with three different imaging devices, before and after the laser treatment. The devices are called IOLMaster 700, CASIA2, and Pentacam AXL. All three take detailed pictures of the front of the eye without touching it. The study team wants to find out whether the artificial lens moves after the laser treatment, how much it moves, whether any movement changes vision or the glasses prescription, and whether the three devices give matching results.

Who can take part

People who had cataract surgery at least three months ago, who now have a cloudy membrane behind the artificial lens, and whose eye doctor has already decided that the laser treatment is needed.

What taking part involves

Taking part does not change the laser treatment in any way. The decision to perform the treatment, the technique, and the laser settings are made by the treating doctor for medical reasons and are not influenced by the study. The study only adds extra measurements before and after the treatment.

There are three study visits:

  • Visit 1, on the day of the laser treatment and before the laser is used. The extra measurements take about 30 to 45 minutes.
  • Visit 2, about one week after the treatment. The extra measurements take about 15 to 20 minutes.
  • Visit 3, about one month after the treatment. The extra measurements take about 30 to 45 minutes.

At each visit the study team checks how well you can see, measures the strength of glasses that gives you the sharpest vision, examines your eye with a slit lamp, measures the pressure inside your eye, and takes images with the imaging devices. All of these are standard eye examinations used in everyday clinical practice. Nothing is inserted into the eye, and there are no injections, no medicines, and no radiation. Drops to widen the pupil are not needed for the study.

Taking part is voluntary. You can stop at any time, without giving a reason and without any disadvantage for your medical care. Your laser treatment and all routine follow-up visits go ahead either way. There is no payment for taking part, and taking part brings no direct medical benefit. However, the detailed examination may reveal something that would not be noticed during routine follow-up, such as raised eye pressure. If this happens, you will be told and any necessary care will be arranged as part of your normal treatment at no extra cost.

Study data are stored under a study code instead of your name.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

BACKGROUND AND RATIONALE

Posterior capsule opacification (PCO) is the most common long-term complication of cataract surgery, and Nd:YAG laser posterior capsulotomy is its established standard treatment. Disruption of the posterior capsule alters the mechanical environment of the capsular bag in which the intraocular lens (IOL) is fixated and may therefore affect IOL positional stability. Because IOL position determines the effective lens position, which is the dominant source of residual refractive prediction error in modern IOL power calculation, any clinically relevant positional change could translate into a measurable refractive shift.

The published evidence is conflicting. Individual studies report posterior IOL displacement with hyperopic shift, anterior displacement with myopic shift, or no measurable change, while the most comprehensive meta-analysis to date (850 eyes from 18 publications) reports population-level stability of anterior chamber depth (ACD) and spherical equivalent up to one month after capsulotomy. Subgroup-specific effects have been described in relation to corneal health status, IOL haptic design, the interval between cataract surgery and capsulotomy, and capsulotomy size.

A methodological limitation common to this literature is that every published study quantifies ACD with a single measurement device. Different technologies define ACD differently, using optical versus geometric measurement principles, corneal epithelium versus endothelium as the anterior reference surface, and device-specific segmentation algorithms. Cross-study comparison is therefore unreliable, and it remains unresolved whether the contradictory findings reflect genuine biological heterogeneity or device-dependent measurement artefact. In addition, automated three-dimensional quantification of IOL tilt and decentration by anterior segment swept-source OCT has not been systematically applied to the post-capsulotomy question, and the IOL platforms routinely implanted at European cataract centres are underrepresented in the available data.

DESIGN

Single-centre, prospective, non-interventional diagnostic cohort study using a paired within-eye pre-post comparison, in which each eye serves as its own control. Consecutive pseudophakic eyes with visually significant PCO scheduled for clinically indicated Nd:YAG capsulotomy are enrolled without pre-selection for IOL model, axial length, PCO morphology, or interval since cataract surgery. Measurement device, operator, and measurement conditions are held constant across time points, so that the paired design isolates the effect of capsulotomy from inter-device and inter-session variability. Simultaneous acquisition on three platforms at each time point additionally permits an inter-device agreement analysis for ACD change that is not achievable in a single-device study.

STUDY VISITS

Visit 1 (baseline) takes place on the day of capsulotomy, before the procedure. Visit 2 follows at one week (plus or minus 3 days) and Visit 3 at one month (plus or minus 7 days) after capsulotomy.

At the two full visits (Visit 1 and Visit 3) the following measurements are acquired in a fixed sequence designed to minimise measurement interference: uncorrected distance visual acuity; IOLMaster 700 optical biometry; CASIA2 anterior segment swept-source OCT; Pentacam AXL Scheimpflug tomography; autorefraction followed by subjective manifest refraction with Jackson cross-cylinder refinement and best-corrected distance visual acuity; and slit-lamp examination including intraocular pressure measurement. Mydriasis is not required by the protocol, and all measurements are performed under natural pupil conditions; if dilation is clinically indicated for other reasons, it is performed only after all study measurements are complete.

At Visit 2, visual acuity, manifest refraction, IOLMaster 700 biometry, slit-lamp examination and tonometry are mandatory, whereas CASIA2 and Pentacam AXL imaging is optional in order to limit patient burden at the interim visit; where performed, it follows the identical standardised protocol and contributes to the agreement analyses. At both post-capsulotomy visits the refractionist is masked to the previous refraction values to avoid anchoring bias.

PARAMETERS

CASIA2: ACD referenced to the posterior corneal surface, anterior chamber angle and volume, IOL tilt (horizontal and vertical) and decentration acquired with the post-operative cataract application, anterior, posterior and total/real keratometry, central corneal thickness, pupil parameters, quality score and analysis area.

IOLMaster 700: ACD referenced to the corneal epithelium, keratometry and total keratometry, axial length, central corneal thickness, white-to-white, pupillometry.

Pentacam AXL: ACD, SimK, total corneal refractive power at the 3.0 mm zone, true net power, posterior keratometry, pachymetry mapping, corneal irregularity indices (ISV, IVA, IHD, KI, CKI), chamber angle and volume, axial length.

Scans that do not meet the manufacturer's quality criteria are repeated once and otherwise documented as failed with the reason specified.

Historical data are extracted from the medical record for each enrolled eye: date and details of the cataract surgery including incision location and technique, implanted IOL model, power, material, optic and haptic design, optic edge geometry and, for toric IOLs, planned cylinder and alignment axis, together with the preoperative biometry and the documented postoperative course.

Capsulotomy parameters are documented immediately after the procedure: laser device, posterior offset, starting and maximum energy level, total energy delivered, number of shots, capsulotomy shape and diameter, contact lens used, peri-procedural medication, and intraprocedural observations including IOL pitting. The study neither prescribes nor modifies the capsulotomy technique, the energy settings, or the capsulotomy size, all of which remain at the discretion of the treating ophthalmologist.

ANALYSIS

The primary analysis set comprises one eye per patient, selected deterministically as the first treated eye within the study period; if both eyes are treated on the same day, the eye is selected at random using a reproducible seed. Bilateral eyes are analysed in a pre-specified sensitivity analysis using generalised estimating equations or linear mixed models to account for within-patient correlation.

The primary endpoint is tested against the null hypothesis of no change using a paired t-test, or a Wilcoxon signed-rank test where the normality assumption is not met, at a two-sided alpha of 0.05. It is the only confirmatory hypothesis specified. All secondary endpoints are explicitly classified as exploratory and hypothesis-generating; each is reported with a two-sided p value and a 95% confidence interval, without family-wise error correction, because they address heterogeneous mechanistic, descriptive and device-agreement questions rather than competing tests of a single hypothesis. Inter-device agreement is reported as estimation only, with bias, 95% limits of agreement and intraclass correlation coefficients, and without hypothesis testing. Pre-specified sensitivity analyses include restriction to corneally stable eyes, exclusion of eyes with Fuchs endothelial corneal dystrophy, exclusion of visits outside the protocol time window, and an alternative clinical relevance threshold for the primary endpoint.

The target sample size is based on the paired comparison of the primary endpoint. Published data report mean ACD changes after capsulotomy between 0.00 and 0.06 mm with within-eye standard deviations of approximately 0.05 to 0.10 mm. At a within-eye standard deviation of 0.08 mm and a two-sided alpha of 0.05, 57 eyes provide at least 80 percent power to detect a mean change of 0.03 mm, and the study is substantially overpowered for the pre-specified clinical relevance threshold. An attrition rate of approximately 10 percent is anticipated.

Reporting follows the STROBE statement for cohort studies, with STARD elements applied to the inter-database agreement analyses.

Tipo de estudo

Observacional

Inscrição (Estimado)

80

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • State of Vienna
      • Vienna, State of Vienna, Áustria, 1130
        • Augenabteilung, Klinik Hietzing, Wiener Gesundheitsverbund

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Método de amostragem

Amostra Não Probabilística

População do estudo

Consecutive pseudophakic patients presenting to the Department of Ophthalmology, Klinik Hietzing, Vienna, Austria, with visually significant posterior capsule opacification for which Nd:YAG laser posterior capsulotomy is clinically indicated. Patients are identified through the routine clinical workflow: the cataract follow-up clinic, referrals from external ophthalmologists, and self-presentation with visual complaints consistent with posterior capsule opacification. Enrolment is consecutive and unselected with respect to IOL model, axial length, time since cataract surgery and morphology of the opacification, so that the cohort reflects the general population of pseudophakic eyes undergoing capsulotomy at the study centre. The decision to perform the capsulotomy is made independently of the study.

Descrição

Inclusion Criteria:

  • Pseudophakic eye with visually significant posterior capsule opacification for which Nd:YAG laser posterior capsulotomy is clinically indicated, defined as a subjective visual complaint attributable to the opacification (reduced visual acuity, glare or reduced contrast) together with objectively documented opacification on slit-lamp examination
  • Previous uneventful phacoemulsification with in-the-bag implantation of a posterior chamber intraocular lens; no restriction on IOL model
  • At least 3 months between the cataract surgery and the baseline study visit
  • Age 18 years or older at enrolment
  • Able to cooperate with the multi-device measurement protocol, including fixation for all three imaging devices and standardized subjective manifest refraction with Jackson cross-cylinder refinement
  • Written informed consent

Exclusion Criteria:

  • Complicated cataract surgery, including posterior capsule rupture, vitreous loss, zonular dialysis, sulcus intraocular lens placement, anterior vitrectomy, or any other deviation from standard in-the-bag implantation
  • Previous intraocular lens exchange, repositioning, or secondary piggyback implantation
  • Previous Nd:YAG posterior capsulotomy of the study eye
  • Previous corneal refractive surgery of the study eye
  • Interval intraocular surgery of the study eye since the cataract surgery, including vitrectomy, glaucoma filtering surgery and corneal transplantation, or intravitreal injection within 4 weeks of a study visit; selective laser trabeculoplasty is not an exclusion criterion
  • Active anterior segment inflammation at the baseline visit
  • Clinically significant corneal pathology precluding reliable keratometry, including corneal oedema, band keratopathy, central corneal scarring, and Fuchs endothelial corneal dystrophy grade 3 or 4 with clinically evident oedema; grades 1 and 2 without oedema are eligible
  • Known intraocular lens instability before capsulotomy, including subluxation, decentration estimated above 1.0 mm, or pseudophacodonesis
  • Cognitive or physical limitations precluding standardized subjective manifest refraction

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Pseudophakic Eyes Undergoing Nd:YAG Laser Posterior Capsulotomy
Pseudophakic eyes with visually significant posterior capsule opacification for which Nd:YAG laser posterior capsulotomy is clinically indicated independently of the study. Each eye is assessed with a standardized multi-device anterior segment protocol immediately before the routine procedure and at one week and one month afterwards, and serves as its own control in a paired within-eye comparison.
Routine Nd:YAG laser posterior capsulotomy performed for visually significant posterior capsule opacification according to the department's standard clinical protocol. Indication, technique, energy settings and capsulotomy size are determined by the treating ophthalmologist and are not modified by the study. Procedural parameters are documented for analysis.
Non-contact anterior segment optical coherence tomography providing anterior chamber depth, anterior chamber angle and volume, automated three-dimensional IOL tilt and decentration, corneal tomography, pachymetry and pupil parameters. Primary device for the primary outcome measure.
on-contact optical biometry providing anterior chamber depth, keratometry, total keratometry, axial length, central corneal thickness, white-to-white and pupillometry.
Scheimpflug-based anterior segment tomography providing anterior chamber depth, SimK, total corneal refractive power, true net power, posterior keratometry, pachymetry mapping, corneal irregularity indices, chamber angle and volume, and axial length.
Autorefraction as starting value followed by subjective manifest refraction with Jackson cross-cylinder refinement, yielding sphere, cylinder, axis and spherical equivalent, plus uncorrected and best-corrected distance visual acuity in logMAR. The refractionist is masked to previous refraction values at the post-capsulotomy visits.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in anterior chamber depth (ACD) measured by anterior segment swept-source OCT
Prazo: Baseline (immediately before capsulotomy) and 1 month (plus or minus 7 days) after capsulotomy
ACD in millimetres, measured from the posterior corneal surface to the anterior IOL surface by automated CASIA2 segmentation. The change is calculated as ACD after capsulotomy minus ACD before capsulotomy. Positive values indicate posterior IOL displacement, negative values anterior displacement. Reported as mean change with standard deviation and 95% confidence interval, together with the proportion of eyes exceeding the pre-specified clinical relevance threshold of 0.05 mm in absolute value.
Baseline (immediately before capsulotomy) and 1 month (plus or minus 7 days) after capsulotomy

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in IOL tilt measured by anterior segment swept-source OCT
Prazo: Baseline and 1 month after capsulotomy
Horizontal and vertical IOL tilt in degrees, measured with the CASIA2 post-operative cataract application. Reported as mean change with standard deviation and as the proportion of eyes with an absolute tilt change of at least 2 degrees.
Baseline and 1 month after capsulotomy
Change in IOL decentration measured by anterior segment swept-source OCT
Prazo: Baseline and 1 month after capsulotomy
IOL decentration in millimetres, measured with the CASIA2 post-operative cataract application. Reported as mean change with standard deviation and as the proportion of eyes with an absolute change of at least 0.3 mm.
Baseline and 1 month after capsulotomy
Change in spherical equivalent from standardized manifest refraction
Prazo: Baseline, 1 week and 1 month after capsulotomy
Spherical equivalent in dioptres, calculated as sphere plus half the cylinder from subjective manifest refraction with Jackson cross cylinder refinement. Positive change indicates hyperopic shift.
Baseline, 1 week and 1 month after capsulotomy
Proportion of eyes with a clinically relevant refractive shift
Prazo: 1 week and 1 month after capsulotomy
Proportion of eyes with an absolute change in spherical equivalent of at least 0.50 dioptres, reported with Wilson 95% confidence intervals.
1 week and 1 month after capsulotomy
Change in refractive cylinder magnitude and axis
Prazo: Baseline, 1 week and 1 month after capsulotomy
Cylindrical magnitude in dioptres and cylinder axis in degrees from standardized manifest refraction in plus-cylinder notation.
Baseline, 1 week and 1 month after capsulotomy
Change in uncorrected and best-corrected distance visual acuity
Prazo: Baseline, 1 week and 1 month after capsulotomy
UDVA and BCDVA in logMAR. Reported as mean change, as the proportion of eyes achieving BCDVA of 0.10 logMAR or better, and as the proportion gaining at least 2 logMAR lines.
Baseline, 1 week and 1 month after capsulotomy
Inter-device agreement for the change in anterior chamber depth
Prazo: Baseline to 1 month after capsulotomy
Agreement of the ACD change between CASIA2, IOLMaster 700 and Pentacam AXL for each device pair, reported as Bland-Altman bias with 95% limits of agreement, intraclass correlation coefficient and the proportion of eyes in which both devices agree on the direction of change. Reported as estimation without hypothesis testing.
Baseline to 1 month after capsulotomy
Inter-device agreement for absolute anterior chamber depth
Prazo: Baseline and 1 month after capsulotomy, analysed separately
Agreement of absolute ACD between CASIA2, IOLMaster 700 and Pentacam AXL for each device pair, reported separately at each time point as Bland-Altman bias with 95% limits of agreement and intraclass correlation coefficient.
Baseline and 1 month after capsulotomy, analysed separately
Change in keratometry
Prazo: Baseline and 1 month after capsulotomy
Mean keratometry, keratometric cylinder and steep axis from IOLMaster 700, CASIA2 anterior keratometry and Pentacam AXL SimK, in dioptres and degrees. The proportion of eyes meeting the pre-specified corneal stability criterion is reported.
Baseline and 1 month after capsulotomy
Change in corneal irregularity indices
Prazo: Baseline and 1 month after capsulotomy
Index of surface variance, index of vertical asymmetry, index of height decentration and keratoconus index measured by Pentacam AXL.
Baseline and 1 month after capsulotomy
Change in central corneal thickness
Prazo: Baseline and 1 month after capsulotomy
Central corneal thickness in micrometres measured by CASIA2 and Pentacam AXL, with the proportion of eyes showing an increase above 10 micrometres as an indicator of endothelial stress.
Baseline and 1 month after capsulotomy
Change in anterior chamber angle and anterior chamber volume
Prazo: Baseline and 1 month after capsulotomy
Anterior chamber angle in degrees and anterior chamber volume in cubic millimetres measured by CASIA2.
Baseline and 1 month after capsulotomy
Correlation between IOL positional change and refractive change
Prazo: Baseline to 1 month after capsulotomy
Spearman correlation of the change in anterior chamber depth, IOL tilt and IOL decentration with the change in spherical equivalent, supplemented by multivariable linear regression with the change in spherical equivalent as dependent variable.
Baseline to 1 month after capsulotomy
Change in toric IOL alignment axis
Prazo: Baseline and 1 month after capsulotomy
Change in the alignment axis of toric IOLs in degrees, assessed by CASIA2 and slit-lamp retroillumination, with the proportion of eyes showing a change of at least 5 and at least 10 degrees. Reported descriptively where the subgroup comprises fewer than 10 eyes.
Baseline and 1 month after capsulotomy
Change in intraocular pressure
Prazo: Baseline, 1 week and 1 month after capsulotomy
Intraocular pressure in mmHg measured by Goldmann applanation tonometry or non-contact tonometry, with the proportion of eyes above 21 mmHg and the proportion with an increase above 5 mmHg. Descriptive safety parameter.
Baseline, 1 week and 1 month after capsulotomy

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de setembro de 2026

Conclusão Primária (Estimado)

1 de agosto de 2027

Conclusão do estudo (Estimado)

1 de agosto de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

30 de agosto de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

30 de agosto de 2026

Primeira postagem (Real)

3 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

30 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • MA15-EK-26-141

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .